---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-025995"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2022-12-02T23:59:59+00:00"
generated_at: "2026-06-21T10:21:37.380083+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Nkarta announces Dec 5 call to review updated NKX019 clinical data; no data in filing

## Summary
- Conference call scheduled for December 5, 2022 at 8:00 a.m. ET to review updated clinical data from NKX019.
- NKX019 is a CD19-directed CAR NK cell therapy for cancer; no specific data provided in the press release.
- Slides will be posted on Nkarta's website; a replay will be available for 4 weeks.

## SEC filing metadata
- accession: 0000950170-22-025995
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2022-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017022025995/0000950170-22-025995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017022025995/nktx-20221202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-025995
- JSON: https://secwatch.observer/filing/0000950170-22-025995.json
- Plain text: https://secwatch.observer/filing/0000950170-22-025995.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.